AAP
JANX icon

Arax Advisory Partners’s Janux Therapeutics JANX Stock Holding History

Arax Advisory Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6K Buy
+1,279
New +$18.5K ﹤0.01% 3970
2025
Q4 		– Sell
-14
Closed -$342 – 4310
2025
Q3 		$342 Buy
+14
New +$341 ﹤0.01% 3404

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Arax Advisory Partners's JANX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Janux Therapeutics (JANX) in Q2 2026: 1,279 shares worth $19.6K. The stake represents ﹤0.01% of the portfolio and ranks #3970 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in JANX as recently as Q3 2025.

Arax Advisory Partners first reported a position in JANX in Q3 2025 and has held it in 2 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Arax Advisory Partners held 1,279 shares of Janux Therapeutics worth $19.6K as of Q2 2026.
  • Janux Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3970 holding.
  • Arax Advisory Partners first reported a position in Janux Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.